ICU

SeaStar is a commercial-stage device company whose entire investable case rests on one FDA-approved product and one unapproved one. QUELIMMUNE — the only FDA-approved pediatric therapy for AKI due to sepsis requiring CRRT (HDE approval Feb 2024, first commercial shipment July 2024) — generated just $1.23M of revenue in FY2025. The +814% growth headline is real but meaningless off a $135K base; this is a product still being introduced to pediatric hospitals one unit at a time, and management explicitly warns revenue 'will fluctuate from quarter to quarter.' Gross margin is a genuine 95.7% (COGS of only $53K), so the technology isn't the problem — scale is. The company remains structurally unprofitable: -$12.2M net loss, -986% operating margin, and a -$152M accumulated deficit that dwarfs the $10.4M of equity.

The disqualifying issue is liquidity. Operating cash flow was -$13.6M in FY2025, yet the last-reported cash balance is $1.82M (FY2024). Even crediting the $13.6M of FY2025 current assets built via financing, a company burning ~$13.6M a year against that base has roughly a year of runway and must raise capital continuously. The 10-K confirms the mechanism — a standby equity purchase agreement (with a one-time financing fee) and notes payable — which is an at-the-market dilution engine. The 54% drop in share count signals a reverse split, the classic tell of a stock fighting to hold listing compliance, not a company returning capital. Retail buyers here are near-certain to be diluted.